Iniciar sesión Regístrese gratis

Edesa Biotech Rentabilidad sobre recursos propios

¿Qué es el Rentabilidad sobre recursos propios de Edesa Biotech?

El Rentabilidad sobre recursos propios de Edesa Biotech, Inc. es -137.98%

¿Cuál es la definición de Rentabilidad sobre recursos propios?



El rendimiento del capital es una medida de la rentabilidad de una empresa en relación con el valor contable del capital contable. Se calcula dividiendo los ingresos netos del año fiscal por el capital contable total.

The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.

Rentabilidad sobre recursos propios de compañías en Sector Health Care en NASDAQ en comparadas con Edesa Biotech

¿Qué hace Edesa Biotech?

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Empresas con rentabilidad sobre recursos propios similar a Edesa Biotech